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Abstract
Background: High-risk (HR) HPV genotypes other than 16 and 18 have been detected in a significant proportion of
immunocompromised females. We aim to evaluate the frequency of HR HPV genotypes in a population of HIV-positive
Caribbean women.
Methods: One hundred sixty-seven consecutive, non-pregnant, HIV-positive females $18 years were recruited in this study.
Each participant received a vaginal examination, PAP smear, and completed a questionnaire. DNA was extracted for HPV
testing in 86 patients.
Results: Mean age was 39.1 years for women positive for HR HPV and 43.1 years for women negative for HR HPV (P value
= 0.040). 78% (130/167) of the women had HR HPV infections; the prevalence of abnormal cervical cytology was 38% among
women who were HR HPV-positive compared to women who were HR HPV-negative (22%). Fifty-one percent of the 86
women with available genotype carried infections with HPV 16 and/or HPV 18; genotypes of unknown risk were also
frequently observed. Women who had a CD4+ count of #200 had 7 times increased odds of carrying HR HPV infection in
comparison to women with CD4+.200.
Conclusions: HR HPV infections in HIV infected females may consist of more than just HPV 16 and 18, but also HPV 52 and
58. Further studies are needed to determine whether HPV 52 and 58 play a significant role in the development of cervical
cytological abnormalities in HIV+ women.
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Introduction
Human Immunodeficiency Virus (HIV) infection leads to a
decline in both the number and function of CD4+ T cells. This
deficiency in the immune system places the infected person at risk
for other infections. For example, Human papillomavirus (HPV) is
the most common sexually transmitted virus that infects the cervix
and is the major etiologic agent for cervical cancer. Studies show
that immunodeficiency increases HPV persistence thus increasing
the risk of cervical cytology abnormalities and invasive cervical
cancer [1,2].
High-risk (HR) HPV types 16 and 18 account for the majority
of all invasive cervical cancers worldwide (56.6% and 16%,
respectively), while HPV 58, 33, 45, 31, 52, 35, 59, 39, 51 and 56
in order of decreasing prevalence account for the other 27.4% of
all invasive cancers worldwide [3]. Similarly in the Caribbean,
56.8% of all invasive cervical cancers are attributed to HPV 16,
and 6.7% to HPV 18; HPV 31, 45, 39, 51, 52, 56, 59 and 73 in
order of decreasing prevalence account for the other 35.5% of
cancers [4]. In 2006, a meta-analysis of HPV infections in HIV-
positive women (n= 5,578) suggested that HPV 16 is less prevalent
among HIV positive women with high-grade cervical lesions, and
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that other subtypes (11, 18, 33, 51, 52, 53, 58 and 61) are also
substantially represented in this population [5]. At the time of the
meta-analysis, however, no studies had been conducted in the
Caribbean islands. In 2009, we conducted a study of cervical HPV
infection in HIV-positive Caribbean women living in the Bahamas
and observed that 46% of women with normal cervical cytology
were infected with HR HPV, and that the prevalence was 100%
for women with high-grade cervical lesions [6]. HPV genotyping
was not evaluated in this study; therefore the type-specific
prevalence and distribution of the various HPV types in HIV-
positive women in the Caribbean population was still unknown.
HIV-positive persons treated with highly active anti-retroviral
therapy (HAART) have reconstitution of the immune system
following a successful lowering of HIV viral load and an increase
in CD4+ T cell counts. These patients are no longer dying
predominantly from opportunistic infections, but may be affected
by other chronic medical illnesses and malignancies. A recent
review by Adler et al [7] suggests that HAART has limited ability
in decreasing HPV-associated cervical cancers in HIV-positive
women. There are no studies addressing this issue conducted for
HIV-positive women in the Caribbean.
In this study, the objectives are to evaluate the frequency and
distribution of HR HPV genotypes in a population of HIV-
positive Caribbean women and determine whether HR HPV
infections other than HPV 16 and 18 are predominant in women
with abnormal cervical cytology.
Methods
Study Population
The study received ethical approval from the Ethics Committee
of the Public Hospital Authority and the University of the West
Indies – Bahamas Campus. All participants provided written
informed consent. Following Institutional Review Board approv-
als, 176 consecutive non-pregnant, HIV sero-positive females
18 years or older were recruited from the Infectious Disease Clinic
at the Princess Margaret Hospital (PMH) in New Providence,
Nassau, Bahamas from February to September, 2008. Cervical
samples were collected through a PAP smear from all women at
the time of the visit, and DNA was extracted for HPV testing. Nine
women were excluded from the study due to insufficient quality
DNA; therefore, the final study population consisted of 167
women. The first 80 patients were part of a previous publication
[6]. All women had a positive HIV status via ELISA and Western
blot methods; none of the women reported having used IV drugs
in their life-time.
The Infectious Disease Clinic at PMH caters to all the Bahaman
Islands where the majority of persons (70%) reside in New
Providence, Nassau and each year about 1,500 HIV-positive
women are seen. This clinic’s mandate is to cater to and treat all
patients regardless of immigration status, nationality or finances by
providing access to antiretrovirals and care. As a result, a small
percentage of patients from other Caribbean countries are also
seen at the clinic. Our study population reflects this demographic,
whereby 93% (n= 155) of women are from Bahamas, while 7%
are from other Caribbean countries (such as Haiti (5%, n= 9) and
Jamaica (2%, n= 3)).
Data collection
Each participant received a vaginal examination, Pap Smear
and completed a questionnaire administered by an interviewer.
The questionnaire collected demographic information, tobacco
and alcohol use, reproductive information such as number of
pregnancies, age at first menses, number of sexual partners, age at
first intercourse, history of sexually transmitted infections.
Clinical information was collected for each participant and
included the number of years diagnosed with HIV, number of
years on HAART and compliance with therapy. In the Infectious
Diseases clinic, patients were initiated on HAART when their
CD4 count was less than 350 cells/mL. For all women, results
from HIV testing (ELISA and Western Blot), CD4 counts (Flow
Cytometry), HIV viral load (Polymerase Chain Reaction (PCR))
and HR HPV status (Hybrid Capture II (HC II)) were recorded in
the patient records in a clinical data base. The HIV testing, viral
load and CD4 counts were performed in the clinical laboratory at
the Princess Margaret Hospital. The HC II assay was performed
in a clinical laboratory at LabCorp in the USA (Miami, Florida).
Review of patient records was performed to obtain these results for
inclusion in this study. The participant’s last CD4 count and HIV
viral load were recorded. These tests were performed either at the
time the cervical sample was obtained or within the previous
two months.
HPV testing
The HC II assay is capable of identifying HR HPV infections
(HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), results
are reported as ‘‘detected’’ or ‘‘not detected’’ and were available
from the medical records for 81 patients in this study. For the
remaining 86 patients, cervical thin-prep samples were shipped to
the United States (Ragin laboratory) where HPV genotyping was
performed using the HPV Linear Array protocol. To confirm that
the extracted DNA samples were PCR amplifiable, the b-globin
gene fragment was amplified using PCO4 and GH20 PCR
primers. All DNA extraction and PCR set-up were performed in a
PCR-clean area separate from the post-DNA amplification areas
in the laboratory. The specific HPV types in each cervical
specimen were identified using a Linear Array HPV genotyping
protocol as previously described [8]. Briefly, the linear array assay
included a PCR-based protocol involving biotin-labeled primers
which detected the 37 most common HPV genotypes identified in
cervical mucosa. The PCR products were denatured and
hybridized to strips containing HPV-specific oligonucleotide
probes. A colorimetric change indicated the presence of a given
HPV type. The HPV types identified by the Linear Array method
includes (Low-risk: 6, 11, 40, 42, 54, 61, 70, 72, 81, CP6108; High
Risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82;
Probable High Risk: 26, 53, 66; and Unknown Risk: 55, 62, 64,
67, 69, 71, 83, 84, IS39).
Both the Linear Array and HC II assays are comparable for HR
HPV status since each detects the same HR HPV genotypes which
are classified based on the previously published risk classification
by Munoz et al. [9]. Therefore the results from both assays were
combined for HR HPV analyses. The Linear Array additionally
detects HPV 73 and 82 which are also classified as ‘‘high-risk’’.
Patient samples that were HCII-positive or had at least one HR
HPV type detected by the Linear Array were categorized as HR
HPV-positive. Patient samples with ‘‘probably high-risk’’ HPV
genotypes were often co- infected with one or more other HR
HPV genotypes (14/16, 88%) therefore were also categorized as
HR HPV-positive. Since low-risk HPV types are not etiologically
liked to cervical carcinogenesis [10] and there is no clinical benefit
for evaluating low-risk HPV status for cervical cancer risk, study
participants who were HPV-negative and/or infected with low-
risk HPV types, and/or infected with undetermined risk were
categorized as HR HPV-negative. Women with HR HPV findings
were counseled and referred for usual clinical care; similarly,
High Risk HPV and HPV Clustering in HIV+ Women
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women with cervical lesions were referred to further testing and
treatment.
Statistical Analysis
Age was categorized into tertiles (19–35 years, 36–45 years, and
46+ years). Age at first intercourse was categorized as a binary
variable based on mean age of responses to the question
(#16 years and .16 years). Current contraceptive use was
categorized as yes/no. Length of time on HAART was categorized
as less than 2 years, 2–4 years, and greater than 4 years. CD4+
cell count and viral load were both divided into two groups based
on the median value for each respective variable. Cervical cytology
reports were categorized into three categories: negative, dysplasia
(which includes low grade squamous intraepithelial lesion [LGSIL]
and high grade squamous intraepithelial lesion [HGSIL]), and
atypical squamous cells of undetermined significance (ASCUS).
Descriptive statistics were generated for demographic, behav-
ioral, and clinical variables according to the presence or absence of
HR HPV infection, using Fisher’s exact test to determine
statistically significant differences between the proportions for
each variable. Multivariable logistic regression models were used
to assess the association of demographic, behavioral, and clinical
variables with HR HPV infections. Pair-wise association of each
variable with HR HPV status was performed. Covariates were
included in the models based on statistically significant associations
with HR HPV status (p,0.05). For the subset of participants
where specific HPV genotypes were available, multivariable
logistic regression models were used to assess the association
between demographic, behavioral, and clinical variables and the
odds of having HR HPV types 16 or 18 versus any other HR HPV
type. Statistical analysis was performed using STATA version 10.1
software (Stata LP, College Station, TX). A P value of #0.05 was
considered statistically significant.
Results
Descriptive Statistics of Overall Study Population
The study population (n = 167) consisted of women, ages 19 to
71 years old (mean age: 40 years). Table 1 summarizes the
demographic and behavioral characteristics of the women
according to HR HPV status. The mean age of HR HPV-positive
women was younger than that of HR HPV-negative women
(39.1 years vs. 43.1 years; P value = 0.040). Overall 78% (130/
167) of the women had HR HPV infections, and the prevalence of
abnormal cervical cytology was 38% (49/130) among women who
were HR HPV-positive compared to women who were HR HPV-
negative (22% (8/37)). Cervical dysplasia rather than ASCUS was
more prominent irrespective of HR HPV status. Seventy-seven
percent (38/49) of HR HPV-positive women with abnormal
cervical cytology had dysplasia compared to 62% (5/8) HR-HPV-
negative women with abnormal cervical cytology. As expected, a
significantly higher proportion of women who carried HR HPV
infections had HIV viral load $400 and CD4 count #200
compared to women who were HR HPV-negative. HR HPV-
positive women were more likely to have had a history of
pregnancy compared to HR HPV-negative women (P=0.048).
Among the women with available HPV genotype data (n = 86),
a wide distribution of HR and low/unknown-risk HPV types was
detected (Figure 1). The prevalence of HR HPV types range from
34.9% to 1.2%, and HPV 18 was the most frequently detected.
HPV 16 and 18 were the most prevalent in younger women,
(#39 years,) while HPV 18 and 58 were most prevalent in older
women (.39 years) (data not shown). Similarly, the prevalence of
Low-Risk HPV types (including genotypes of unknown risk)
ranged from 26.7% to 1.25%; HPV 62, a genotype with unknown
risk, was most frequently detected. Fifty-one percent of the 86
women with available genotype carried infections with HPV 16
and/or HPV 18. The majority, 73/86 (85%), carried multiple
cervical HPV infections of any HPV type ranging from two to
fifteen different HPVs in a single sample. With regard to HR HPV
genotypes, women carried at least one or as many as 7 in any given
sample.
Multivariable Analysis
Women who had a CD4+ count of #200 had 7 times increased
odds of carrying HR HPV infection (Adjusted Odds Ratio [Adj
OR] 7.27, 95% Confidence Interval [CI] 1.41- 37.53-Table 2).
There were no statistically significant associations between the
other covariates and HR HPV infections (i.e. age, number of years
on HAART, viral load and cervical cytology).
Among the 86 women for which specific HPV genotype data
were available, 76 had HR HPV infections. For these women,
after adjusting for possible confounders, women with a CD4 count
#200 cell m/L appeared more likely to be HPV 16/18 positive
compared to women with a higher CD4 count, but this association
was not statistically significant. No other variable was associated
with carrying an HPV 16/18 infection in comparison to having
another HR infection (Table 3).
Discussion
In this sample of HIV-positive Caribbean women, we report
that HR types 16 and 18 were among the most commonly
diagnosed HPVs, and that infections with HR HPV types 52 and
58 are frequent. Other studies involving HIV-positive women in
the US and Africa have reported a high prevalence of HR HPV
types other than HPV 16 and 18, and our study among
Caribbean women is in line with these results. Sherestha et al
noted an increased incidence and prevalence of HPV 58, 53/66,
68/70 and 31/33/35, in African American HIV-positive females
[11]; these subtypes were more frequent than HPV 16 and 18.
Similarly, Luque et al [12] determined that high-risk types other
than 16 and 18 were the most prevalent in a diverse population
of HIV-positive women in Rochester, New York. Types 56 and
53 occurred most frequently in that population, followed by
HPV 16, 58, and 52. A Ugandan study with an HIV-positive
female population conducted by Banura et al [13] revealed high-
risk types 52, 33, 51, and 16 in this order. Finally, in Zambia,
145 HIV-positive women were evaluated and HPV 52, 58 and
53 was the most prevalent while HPV 16, 35 and 45 were less
common in this study population [14].
The majority of women in our sample carried multiple HR
HPV infections; this could be attributed, among others, to the
immunosuppressive state due to HIV infection. Patel et al.
reported that the risk of abnormal cervical cytology was increased
among women who carried multiple HPV infections (OR=6.0;
95% CI: 2.3–15.7) [15]; this may be partly attributed to a high
prevalence of HPV infection, and to an increased likelihood of
persistent infection due to HIV status [16,17,18,19]. Studies show
that infections with multiple high-risk HPV types may act
synergistically in cervical cancer development [20]. Therefore,
the recommendation of routine cervical cancer screening in HIV-
positive women is appropriate. At the time of this study cervical
cancer screening, although available through the public clinics,
was not routinely performed as part of the Infectious Diseases
Clinic’s Programme. Since the completion of this study, the
Gynecology department and HIV clinics at the Princess Margaret
High Risk HPV and HPV Clustering in HIV+ Women
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Hospital have revised their policies and now encourages HIV-
positive women to have their Pap Smears at least annually.
Another interesting finding is that 78% of the women carried
HR HPV subtypes, but only 38% presented with abnormal
cervical cytology; this suggests that the majority of these infections
were likely transient rather than persistent, or that these were new
infections. In addition, a high rate of cervical abnormalities was
observed among women without evidence of HR HPV types yet
cervical dysplasia rather than ASCUS was more frequently
diagnosed. Assuming that HPV remains the main risk factor for
cervical cancer in the Caribbean, this finding may indicate that
other HPV types, considered low risk, are actually responsible,
alone or in combination with specific environmental/behavioral
factors, for the observed cervical abnormalities.
There is limited epidemiologic evidence of a specific role of
HPV 52 and 58 in cancer development in HIV-positive women.
Although high-risk HPV types 16 and 18 are known to be
associated with more than 70% of all cervical cancer cases, few
studies suggest that this may not necessarily hold true for
immunocompromised populations of non-European descent.
Sahasrabuddhe et al. screened over 145 HIV-positive Zambian
women and detected squamous cell carcinoma in 28 females.
Thirteen (46.4%) SCC cases were positive for HPV 52, and 10
(35.7%) cases were positive for both HPV 58 and 16 [14].
Table 1. Summary of demographic and behavioral characteristics of Bahamas HIV-positive women according to their HR HPV
status.
Characteristic HPV HR Positive (%) HPV HR Negative (%) P valuew
N=130 N= 37
Age (years) 0.065
19–35 51 (39.2) 7 (18.9)
36–45 43 (33.1) 16 (43.2)
46+ 36 (27.7) 14 (37.8)
Age at 1st intercourse (years) 0.853
#16 70 (53.9) 19 (51.3)
.16 60 (46.1) 18 (48.7)
Current contraceptive use* 0.563
No 73 (58.4) 18 (51.4)
Yes 52 (41.6) 17 (48.6)
Number of Pregnancies 0.048
0 9 (6.9) 0
1–3 63 (48.5) 13 (35.1)
.3 58 (44.6) 24 (64.9)
Presently on HAART{ 1.000
Yes 105 (81.4) 29 (80.6)
No 24 (18.6) 7 (19.4)
Number of Years on HAART{ 0.063
,2 years{{ 33 (31.4) 6 (20.7)
2–4 years 43 (41.0) 8 (27.6)
.4 years 29 (27.6) 15 (51.7)
Number of Years known HIV-positive 0.579
,3 51 (39.2) 11 (29.7)
3–9 47 (36.2) 15 (40.5)
.9 years 32 (24.6) 11 (29.7)
Last Viral Load mL21 0.001
,400 56 (43.1) 27 (73.0)
$400 74 (56.9) 10 (27.0)
Last CD4 Count cell/mL ,.0001
#200 55 (42.3) 3 (8.1)
.200 75 (57.7) 34 (91.9)
Cervical Cytology 0.079
Normal 81 (62.3) 29 (78.4)
Abnormal¥ 49 (37.7) 8 (21.6)
wFisher’s exact test p-values; *Data missing for 7 women; Yes: birth control and male condoms, No: abstinence, sterilization and no method of birth control used; {Data
missing for 2 women; {{Includes women who answered ‘‘yes’’ to being on treatment but also answered ‘‘0’’ to number of years on treatment; ¥Includes ASCUS, Reactive
and dysplasia.
doi:10.1371/journal.pone.0085429.t001
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Similarly, Maranga et al. reported a lower prevalence of HPV 16
and 18 in HIV-positive women with invasive cervical carcinoma
compared to HIV-negative women with invasive cervical carci-
noma [21]. In the present study, none of the study participants had
invasive cervical carcinoma; therefore, associations between
HPV52 and 58 with SCC cannot be explored in this sample.
However, the next step will be to follow prospectively these women
to determine whether these HR HPV types are associated with
cancer development. This has public health relevance since the
current vaccines only target types 16 and 18, thus offering little
protection if other HR HPV types are shown to play a role in the
immunocompromised population.
Our study has several limitations: despite the fact that we
enrolled all consecutive patients from the Clinic, we cannot
exclude that some selection bias occurred, thus we cannot affirm
that the results have external validity for the entire HIV positive
community in the Bahamas. In addition, only a subset of the study
population had available type-specific HPV information. Another
limitation in this study is that, given the retrospective nature of the
design, the participant’s last CD4 count and HIV viral load were
either performed at the time of enrollment or within the previous
Figure 1. Genotype-specific distribution of high-risk and low/undetermined-risk HPV types detected in HIV-positive women. The
prevalence does not total 100% since several women were infected with multiple HPV types.
doi:10.1371/journal.pone.0085429.g001
Table 2. Association between clinical factors and HR HPV infection (n = 167).
Variable Adjusted Odds Ratio* 95% Confidence Interval
Number of Years on HAART
,2 years 1.0 ref
2–4 years 1.54 (0.43–5.56)
.4 years 0.55 (0.17–1.82)
Last CD4 count cell/mL
.200 1.0 ref
#200 7.27 (1.41–37.53)
Last Viral Load mL21
,400 1.0 ref
$400 1.62 (0.47–5.51)
Cervical Cytology
Negative 1.0 ref
ASCUS & Reactive 0.74 (0.16–3.44)
Dysplasia (HGSIL or LGSIL) 1.75 (0.42–7.32)
*Adjusted for age, length of time on HAART, CD4+ count, viral load, and cervical abnormalities.
doi:10.1371/journal.pone.0085429.t002
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two months. In the first month after initiating HAART, CD4
count will start to rise, and will continue to rise for the first three
years on average before reaching a plateau. It is possible that the
levels of CD4 and viral load may be inaccurate in patients where
CD4 and viral load data were obtained prior to enrollment, and
HAART was initiated at the time of enrollment.
Another limitation of this study is that we examined exfoliated
cervical cells rather than cervical biopsies. A recent study
compared HPV prevalence and genotype infections between
exfoliated cells and the corresponding cervical biopsy from women
who HIV-positive [22]. Among women diagnosed with CIN2/3,
the prevalence of HPV and multiple HPV types were similar in the
biopsy compared to the exfoliated cells. This was in contrast to
HIV-positive women with normal cervical cytology where the
prevalence of HPV and multiple HPV types was higher in
exfoliated cells compared to biopsy specimens. Another limitation
is that the retrospective nature of the study does not allow us to
assess a causal relationship between the length of time on HAART
and the risk of developing abnormal cervical cytology.
Our findings support the need for follow-up of HIV-positive
women in a longitudinal study in the Bahamas. The data
generated from these efforts would provide important clinical
information related to HPV persistence and the dynamics of
multiple infections with HR HPV types in this population.
Comparisons of HPV infections between cervical biopsies and
exfoliated cells would provide meaningful information for the
development of appropriate screening and HPV triage protocols
needed for the evaluation and management of HPV infections in
HIV-positive women.
Conclusions
To our knowledge our work represents the first study of HR
HPV infections in a unique population of Black HIV-positive
women treated in the Bahamas. Our findings correlate with what
has been reported in other populations. This information will need
to be confirmed in larger studies but already warrants the
significance of HPV screening in HIV-positive populations.
Furthermore, the findings from our study could provide some
insight on the potential efficacy of the current HPV vaccines in a
population where HIV infection is wide-spread.
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